|
We asked 40 pharma leaders, do you agree that the potential fees charged by the EMA for pharmacovigilance activities are unjustifiably high?
| Yes |
67% |
| No |
22% |
| The wording of the fees is not clear |
11% |
 |
|
|
|
|
|
|
|
9 October, 2012
|
| In this Issue |
|
Biopharma Boom Predicted
A new report from GBI Research forecasts that the global biopharmaceutical market will be worth more than $320 billion by 2020, up from just $138 billion in 2011. Read more... |
Takeda’s Big Plans for BRIC — minus India
The completion last month of Takeda’s $96 million production plant in Yaroslavl, Russia, is further proof of the company’s rapid and expansive efforts to play ‘catch-up’ in the emerging markets, particularly the BRIC countries. That is, the BRIC countries minus India. Pharm Exec speaks to Takeda Chief Commercial Officer Dr. Frank Morich. More... |
Pharm Exec’s Industry Audit — Think Small, Be Stealthy
In this video, Pharm Exec Editor-in-Chief William Looney presents an overview of the magazine’s lead feature this month. More... |
Selling Specialty Drugs in China
Companies like Sanofi and Pfizer, despite their own in-country resources, are apparently achieving better returns after partnering with US-based SciClone Pharmaceuticals. SciClone CEO Friedhelm Blobel talks to Ben Comer. More...
|
|
|
|
